Enliven Therapeutics Inc
ELVN
Company Profile
Business description
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Contact
6200 Lookout Road
BoulderCO80301
USAT: +1 720 647-8519
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
62
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,510.70 | 43.70 | 0.52% |
| CAC 40 | 7,861.05 | 10.95 | 0.14% |
| DAX 40 | 23,564.09 | 2.45 | -0.01% |
| Dow JONES (US) | 42,410.10 | 1,160.72 | 2.81% |
| FTSE 100 | 8,601.61 | 3.37 | -0.04% |
| HKSE | 23,108.27 | 441.19 | -1.87% |
| NASDAQ | 18,708.34 | 779.43 | 4.35% |
| Nikkei 225 | 38,183.26 | 539.00 | 1.43% |
| NZX 50 Index | 12,786.74 | 109.99 | 0.87% |
| S&P 500 | 5,844.19 | 184.28 | 3.26% |
| S&P/ASX 200 | 8,269.00 | 35.50 | 0.43% |
| SSE Composite Index | 3,374.87 | 5.63 | 0.17% |